Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019032957) REPROGRAMMING OF CD8 T CELLS WITH CXCL12 SIGNALING INHIBITORS
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/032957 International Application No.: PCT/US2018/046202
Publication Date: 14.02.2019 International Filing Date: 10.08.2018
IPC:
A61K 35/17 (2015.01) ,C12N 5/0783 (2010.01) ,A61P 35/00 (2006.01) ,C07K 14/52 (2006.01)
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
Applicants:
THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street Boston, Massachusetts 02114, US
Inventors:
POZNANSKY, Mark, C.; US
Agent:
SCHWARTZMAN, Robert, A.; Myers Bigel, P.A. P.O. Box 37428 Raleigh, North Carolina 27627, US
Priority Data:
62/544,33911.08.2017US
62/609,60522.12.2017US
Title (EN) REPROGRAMMING OF CD8 T CELLS WITH CXCL12 SIGNALING INHIBITORS
(FR) REPROGRAMMATION DE LYMPHOCYTES T CD8 AVEC DES INHIBITEURS DE SIGNALISATION CXCL12
Abstract:
(EN) The present invention relates to methods and compositions for decreasing the level of PD-1 on a CD8+ T cell, converting a CD25+ Foxp3+ regulatory T cell to a CD25- Foxp3+ helper-like T cell, and reprogramming subpopulations of T cells to a phenotype suitable to enhance an immunotherapy treatment using an inhibitor of CXCL12 signaling.
(FR) La présente invention concerne des procédés et des compositions pour diminuer le taux de PD-1 sur un lymphocyte T CD8+, convertir un lymphocyte T régulateur CD25+ Foxp3+ en lymphocyte T de type auxiliaire CD25- Foxp3+, et reprogrammer des sous-populations de lymphocytes T dans un phénotype adapté pour améliorer un traitement d'immunothérapie au moyen d'un inhibiteur de la signalisation CXCL12.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)